Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Motor Activity 20 Polycystic Ovary Syndrome 10 Prostatic Neoplasms 7 Breast Neoplasms 6 Neoplasms 5 Colorectal Neoplasms 4 Insulin Resistance 3 Lung Neoplasms 2 Fatigue 2 Esophageal Neoplasms 2 Cardiotoxicity 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Rectal Neoplasms 1 Primary Dysautonomias 1 Pediatric Brain Tumor 1 Ovarian Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Multiple Endocrine Neoplasia Type 1 1 Lymphoma, Follicular 1 Lupus Erythematosus, Systemic 1 Inflammation 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Head and Neck Neoplasms 1 Gastrointestinal Neoplasms 1 Disease 1 Diabetes Mellitus, Type 1 1 Chemotherapy-Related Cognitive Impairment 1 Cardiovascular Diseases 1

Interventions

Adalimumab 19 Etanercept 16 Methotrexate 11 Infliximab 8 tocilizumab 7 Rituximab 7 golimumab 6 Abatacept 6 tofacitinib 5 Tumor Necrosis Factor Inhibitors 5 olokizumab 4 Certolizumab Pegol 4 Antirheumatic Agents 3 Saline Solution 2 RC-18 2 Nivolumab 2 Leflunomide 2 veltuzumab 1 upadacitinib 1 secukinumab 1 sarilumab 1 mavrilimumab 1 entecavir 1 cabozantinib 1 baricitinib 1 andecaliximab 1 Vitamin D 1 Vaccines 1 TACI receptor-IgG Fc fragment fusion protein 1 Syringes 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Arthritis, Rheumatoid × High-Intensity Interval Training × Clear all

NCT05215509 2024-02-02

RABEX

Rigshospitalet, Denmark

Phase NA Completed

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡